Could a tiny dose of IL-2 tame ALS?
NCT ID NCT02059759
First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tested whether a low dose of interleukin-2 (IL-2), a protein that helps regulate the immune system, is safe and can increase regulatory T cells in people with ALS. 36 participants received either IL-2 or a placebo for five days. The goal was to see if this approach could calm harmful inflammation and potentially slow the disease, but it is not a cure and ongoing management is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Montpellier - Hôpital Gui de Chauliac
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.